

CITATION REPORT

List of articles citing

Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: A Longitudinal Study

DOI: 10.1001/jamaneurol.2019.1424
JAMA Neurology, 2019, 76, 915-924.

Source: <https://exaly.com/paper-pdf/73073486/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
401	Prospects and challenges of imaging neuroinflammation beyond TSPO in Alzheimer's disease. 2019 , 46, 2831-2847		25
400	Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model. 2019 , 39, 7428-7437		12
399	Targeting apolipoprotein E for treating Alzheimer's disease. 2019 , 709, 134366		1
398	Kynurenines, Neuropsychiatric Symptoms, and Cognitive Prognosis in Patients with Mild Dementia. 2019 , 12, 1178646919877883		8
397	When Does Alzheimer's Disease Really Start? The Role of Biomarkers. 2019 , 20,		27
396	Cerebrospinal fluid amyloid levels are associated with delayed memory retention in cognitively normal biomarker-negative older adults. 2019 , 84, 90-97		3
395	The bivariate distribution of amyloid- β and tau: relationship with established neurocognitive clinical syndromes. 2019 , 142, 3230-3242		77
394	Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. 2019 , 179, 312-339		721
393	Current and Emerging Pharmacological Targets for the Treatment of Alzheimer's Disease. 2019 , 72, S145-S176	19	
392	Sequential amyloid- β and tau accumulation foreshadows cognitive decline. 2019 , 15, 433		1
391	Error in Figure 3. <i>JAMA Neurology</i> , 2019 , 76, 986	17.2	
390	Different aspects of Alzheimer's disease-related amyloid β peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia. 2019 , 7, 178		16
389	Neuroinflammation as a Factor of Neurodegenerative Disease: Thalidomide Analogs as Treatments. 2019 , 7, 313		49
388	A Longitudinal Study of Epileptic Seizures in Alzheimer's Disease. 2019 , 10, 1266		16
387	Testing a MultiTEP-based combination vaccine to reduce A β and tau pathology in Tau22/5xFAD bigenic mice. 2019 , 11, 107		10
386	Diagnostic biomarkers of Alzheimer's disease: A state-of-the-art review. 2019 , 1, 100005		56
385	Cerebrospinal fluid proteomics and biological heterogeneity in Alzheimer's disease: A literature review. 2020 , 57, 86-98		23

384	HSP70 and HSP90 in neurodegenerative diseases. 2020 , 716, 134678	13
383	Error in Text. <i>JAMA Neurology</i> , 2020 , 77, 265	17.2
382	Evolution of anosognosia in alzheimer's disease and its relationship to amyloid. 2020 , 87, 267-280	23
381	Dietary Fatty Acid Factors in Alzheimer's Disease: A Review. 2020 , 78, 887-904	4
380	Cross-sectional associations of amyloid burden with semantic cognition in older adults without dementia: A systematic review and meta-analysis. 2020 , 192, 111386	4
379	Predicting future rates of tau accumulation on PET. 2020 , 143, 3136-3150	25
378	Associations between Vascular Function and Tau PET Are Associated with Global Cognition and Amyloid. 2020 , 40, 8573-8586	23
377	CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer's disease. 2020 , 12, 88	6
376	Passive immunotherapies targeting A β and tau in Alzheimer's disease. 2020 , 144, 105010	27
375	Small molecule modulation of the p75 neurotrophin receptor inhibits multiple amyloid beta-induced tau pathologies. 2020 , 10, 20322	11
374	Synergy between amyloid- β and tau in Alzheimer's disease. 2020 , 23, 1183-1193	207
373	MA-[D-Leu-4]-OB3, a small molecule synthetic peptide leptin mimetic, improves episodic memory, and reduces serum levels of tumor necrosis factor-alpha and neurodegeneration in mouse models of Type 1 and Type 2 Diabetes Mellitus. 2020 , 1864, 129697	5
372	Effects of polygenic risk for Alzheimer's disease on rate of cognitive decline in normal aging. 2020 , 10, 250	9
371	Association of tau accumulation and atrophy in mild cognitive impairment: a longitudinal study. 2020 , 34, 815-823	4
370	Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval. 2020 , 12, 95	85
369	Elevated Tau PET Signal Depends on Abnormal Amyloid Levels and Correlates with Cognitive Impairment in Elderly Persons without Dementia. 2020 , 78, 395-404	1
368	Nrf2: a dark horse in Alzheimer's disease treatment. 2020 , 64, 101206	38
367	PET Amyloid and Tau Status Are Differently Affected by Patient Features. 2020 , 78, 1129-1136	0

366	Pre-clinical dose-ranging efficacy, pharmacokinetics, tissue biodistribution, and toxicity of a targeted contrast agent for MRI of amyloid deposition in Alzheimer's disease. 2020 , 10, 16185	4
365	Sequence of Alzheimer disease biomarker changes in cognitively normal adults: A cross-sectional study. 2020 , 95, e3104-e3116	13
364	Evaluation of Imaging Windows for Tau PET Imaging Using F-PI2620 in Cognitively Normal Individuals, Mild Cognitive Impairment, and Alzheimer's Disease Patients. 2020 , 19, 1536012120947582	4
363	Principal components of tau positron emission tomography and longitudinal tau accumulation in Alzheimer's disease. 2020 , 12, 114	3
362	Alzheimer's Retinopathy: Seeing Disease in the Eyes. 2020 , 14, 921	24
361	Development and Validation of a High Sensitivity Assay for Measuring p217 + tau in Cerebrospinal Fluid. 2020 , 77, 1417-1430	10
360	Unmasking selective path integration deficits in Alzheimer's disease risk carriers. 2020 , 6, eaba1394	13
359	Cerebral blood flow decrease as an early pathological mechanism in Alzheimer's disease. 2020 , 140, 793-810	47
358	Correction of microtubule defects within A β plaque-associated dystrophic axons results in lowered A β release and plaque deposition. 2020 , 16, 1345-1357	5
357	Sleep Disturbance Forecasts β Amyloid Accumulation across Subsequent Years. 2020 , 30, 4291-4298.e3	36
356	The Other Side of Alzheimer's Disease: Influence of Metabolic Disorder Features for Novel Diagnostic Biomarkers. 2020 , 10,	4
355	Peroxiredoxin 6 mediates protective function of astrocytes in A β proteostasis. 2020 , 15, 50	9
354	Relationship between comprehensive geriatric assessment and amyloid PET in older persons with MCI. 2020 , 20, 337	7
353	Normalization of CSF pTau measurement by A β improves its performance as a biomarker of Alzheimer's disease. 2020 , 12, 97	8
352	Vaccination against β Amyloid as a Strategy for the Prevention of Alzheimer's Disease. 2020 , 9,	4
351	Tau PET and relative cerebral blood flow in dementia with Lewy bodies: A PET study. 2020 , 28, 102504	5
350	Non-Amyloid Approaches to Disease Modification for Alzheimer's Disease: An EU/US CTAD Task Force Report. 2020 , 7, 1-6	3
349	TFEB regulates lysosomal exocytosis of tau and its loss of function exacerbates tau pathology and spreading. 2020 ,	20

348	Longitudinal trajectories of Alzheimer's ATN biomarkers in elderly persons without dementia. 2020 , 12, 55	6
347	Ketone production by ketogenic diet and by intermittent fasting has different effects on the gut microbiota and disease progression in an Alzheimer's disease rat model. 2020 , 67, 188-198	18
346	The Role of P2X7 Receptor in Alzheimer's Disease. 2020 , 13, 94	16
345	The Alzheimer's Prevention Initiative Composite Cognitive Test: a practical measure for tracking cognitive decline in preclinical Alzheimer's disease. 2020 , 12, 66	6
344	Bridging Integrator-1 protein loss in Alzheimer's disease promotes synaptic tau accumulation and disrupts tau release. 2020 , 2,	7
343	2020 Alzheimer's disease facts and figures. 2020 , 16, 391	984
342	APOE ϵ 4 potentiates the relationship between amyloid- β and tau pathologies. 2020 ,	23
341	Prevention of dementia in an ageing world: Evidence and biological rationale. 2020 , 64, 101045	26
340	Basal forebrain volume reliably predicts the cortical spread of Alzheimer's degeneration. 2020 , 143, 993-1009	28
339	Functional Brain Network Connectivity Patterns Associated With Normal Cognition at Old-Age, Local β amyloid, Tau, and APOE4. 2020 , 12, 46	8
338	A Novel Individual Metabolic Brain Network for 18F-FDG PET Imaging. 2020 , 14, 344	5
337	The Toxicity and Polymorphism of β Amyloid Oligomers. 2020 , 21,	27
336	Extracellular vesicle biomarkers of Alzheimer's disease associated with sub-clinical cognitive decline in late middle age. 2020 , 16, 1293-1304	27
335	Targeting Pathological Tau by Small Molecule Inhibition of the Poly(A):MSUT2 RNA-Protein Interaction. 2020 , 11, 2277-2285	7
334	Functional connectivity between the entorhinal and posterior cingulate cortices underpins navigation discrepancies in at-risk Alzheimer's disease. 2020 , 90, 110-118	7
333	Compound screening in cell-based models of tau inclusion formation: Comparison of primary neuron and HEK293 cell assays. 2020 , 295, 4001-4013	5
332	Alzheimer's disease beyond amyloid: Can the repetitive failures of amyloid-targeted therapeutics inform future approaches to dementia drug discovery?. 2020 , 177, 113945	26
331	Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer's disease. 2020 , 8, 13	23

330	Regional [¹⁸ F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer's disease. 2020 , 47, 2866-2878	11
329	The Effects of Tau, Amyloid, and White Matter Lesions on Mobility, Dual Tasking, and Balance in Older People. 2021 , 76, 683-691	2
328	Defining a Centiloid scale threshold predicting long-term progression to dementia in patients attending the memory clinic: an [¹⁸ F] flutemetamol amyloid PET study. 2021 , 48, 302-310	9
327	Longitudinal Cognitive and Biomarker Measurements Support a Unidirectional Pathway in Alzheimer's Disease Pathophysiology. 2021 , 89, 786-794	19
326	The β Secretase BACE1 in Alzheimer's Disease. 2021 , 89, 745-756	107
325	Retinal changes in Alzheimer's disease- integrated prospects of imaging, functional and molecular advances. 2021 , 82, 100899	25
324	Phosphorylated full-length Tau interacts with 14-3-3 proteins via two short phosphorylated sequences, each occupying a binding groove of 14-3-3 dimer. 2021 , 288, 1918-1934	2
323	Association of Initial β Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment. <i>JAMA Neurology</i> , 2021 , 78, 217-228	17.2 13
322	Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum. 2021 , 144, 325-339	42
321	Defining the Lowest Threshold for Amyloid-PET to Predict Future Cognitive Decline and Amyloid Accumulation. 2021 , 96, e619-e631	13
320	Regional Tau Effects on Prospective Cognitive Change in Cognitively Normal Older Adults. 2021 , 41, 366-375	7
319	An evaluation of the amyloid cascade model using in vivo positron emission tomographic imaging. 2021 , 21, 14-23	1
318	Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative. 2021 , 26, 429-442	70
317	APOE interacts with tau PET to influence memory independently of amyloid PET in older adults without dementia. 2021 , 17, 61-69	11
316	Systems-based proteomics to resolve the biology of Alzheimer's disease beyond amyloid and tau. 2021 , 46, 98-115	18
315	The Potential Roles of Redox Enzymes in Alzheimer's Disease: Focus on Thioredoxin. 2021 , 13, 1759091421994351	351
314	Analysis of amyloid and tau deposition in Alzheimer's disease using C-Pittsburgh compound B and F-THK 5351 positron emission tomography imaging. 2021 , 20, 61-72	1
313	Development and validation of a high-sensitivity assay for measuring p217+tau in plasma. 2021 , 13, e12204	5

312	Platform Trials to Expedite Drug Development in Alzheimer’s Disease: A Report from the EU/US CTAD Task Force. 2021 , 8, 306-312	5
311	Functional nanoassemblies for the diagnosis and therapy of Alzheimer’s diseases. 2021 , 13, e1696	1
310	Amyloid and APOE Status of Screened Subjects in the Elenbecestat MissionAD Phase 3 Program. 2021 , 8, 218-223	4
309	Neurofibrillary tau depositions emerge with subthreshold cerebral beta-amyloidosis in down syndrome. 2021 , 31, 102740	0
308	Speech pause distribution as an early marker for Alzheimer’s disease.	2
307	Alzheimer’s disease: Epidemiological characteristics and its prevention. 2021 , 50, 57-72	
306	Amyloid-PET imaging offers small improvements in predictions of future cognitive trajectories. 2021 , 31, 102713	1
305	Tau aggregates are RNA-protein assemblies that mis-localize multiple nuclear speckle components.	0
304	PET and SPECT Imaging of Neurodegenerative Diseases. 2021 , 1309-1334	
303	Reduced [F]flortaucipir retention in white matter hyperintensities compared to normal-appearing white matter. 2021 , 48, 2283-2294	2
302	Association of A β deposition and regional synaptic density in early Alzheimer’s disease: a PET imaging study with [C]UCB-J. 2021 , 13, 11	16
301	Cross-Linked Amyloid β Protein Oligomers: A Missing Link in Alzheimer’s Disease Pathology?. 2021 , 125, 1307-1316	0
300	Pathobiology and Management of Alzheimer’s Disease. 2021 , 57, 108-117	1
299	Longitudinal amyloid and tau accumulation in autosomal dominant Alzheimer’s disease: findings from the Colombia-Boston (COLBOS) biomarker study. 2021 , 13, 27	12
298	Clinically oriented Alzheimer’s biosensors: expanding the horizons towards point-of-care diagnostics and beyond.. 2021 , 11, 20403-20422	0
297	Dendritic Spine Remodeling and Synaptic Tau Levels in PS19 Tauopathy Mice. 2021 , 455, 195-211	1
296	Arrayed CRISPR reveals genetic regulators of tau aggregation, autophagy and mitochondria in Alzheimer’s disease model. 2021 , 11, 2879	5
295	Effects of Alzheimer’s and Vascular Pathologies on Structural Connectivity in Early- and Late-Onset Alzheimer’s Disease. 2021 , 15, 606600	0

294	Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. 2021 , 48, 2110-2120	9
293	Clinical validity of increased cortical uptake of [F]flortaucipir on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase biomarker development framework. 2021 , 48, 2097-2109	14
292	Associations between plasma neurofilament light, in vivo brain pathology, and cognition in non-demented individuals with autosomal-dominant Alzheimer's disease. 2021 , 17, 813-821	4
291	Mutual structural effects of unmodified and pyroglutamylated amyloid β peptides during aggregation. 2021 , 27, e3312	0
290	Cannabis Sativa L. Flower and Bud Extracts inhibited In vitro Cholinesterases and b-Secretase Enzymes Activities: Possible Mechanisms of Cannabis use in Alzheimer Disease. 2021 ,	2
289	Tau-PET and in vivo Braak-staging as a prognostic marker in Alzheimer's disease.	0
288	Detecting Alzheimer's disease biomarkers with a brief tablet-based cognitive battery: sensitivity to A β and tau PET. 2021 , 13, 36	3
287	PET measurement of longitudinal amyloid load identifies the earliest stages of amyloid-beta accumulation during Alzheimer's disease progression in Down syndrome. 2021 , 228, 117728	6
286	Microglia show differential transcriptomic response to A β peptide aggregates ex vivo and in vivo.	
285	An Open Question: Is the A Adenosine Receptor a Novel Target for Alzheimer's Disease Treatment?. 2021 , 12, 652455	8
284	Recent Advances in Imaging of Preclinical, Sporadic, and Autosomal Dominant Alzheimer's Disease. 2021 , 18, 709-727	1
283	Glucose metabolism reflects local atrophy and tau pathology in symptomatic Alzheimer's disease.	0
282	Relationship between brain AD biomarkers and episodic memory performance in healthy aging. 2021 , 148, 105680	2
281	2021 Alzheimer's disease facts and figures. 2021 , 17, 327-406	474
280	Update on neuroimaging in Alzheimer's disease. 2021 , 34, 525-531	2
279	Baseline cognition is the best predictor of 4-year cognitive change in cognitively intact older adults. 2021 , 13, 75	5
278	Recent advances in pre-clinical diagnosis of Alzheimer's disease. 2021 , 1	
277	F-18 ML-104 tau PET imaging in mild cognitive impairment. 2021 , 42, 914-921	

276	Sequence of proteome profiles in preclinical and symptomatic Alzheimer's disease. 2021 , 17, 946-958	4
275	Glucose metabolism in the right middle temporal gyrus could be a potential biomarker for subjective cognitive decline: a study of a Han population. 2021 , 13, 74	8
274	Alzheimer's disease: An evolving understanding of noradrenergic involvement and the promising future of electroceutical therapies. 2021 , 11, e397	8
273	Multimodal, label-free fluorescence and Raman imaging of amyloid deposits in snap-frozen Alzheimer's disease human brain tissue. 2021 , 4, 474	5
272	Association of Midlife Depressive Symptoms with Regional Amyloid- β and Tau in the Framingham Heart Study. 2021 , 82, 249-260	3
271	Alzheimer disease. 2021 , 7, 33	114
270	The Effects of Amyloid and Tau on Functional Network Connectivity in Older Populations. 2021 , 11, 599-612	2
269	Comparing PET and MRI Biomarkers Predicting Cognitive Decline in Preclinical Alzheimer Disease. 2021 ,	5
268	Network interdigitations of Tau and amyloid-beta deposits define cognitive levels in aging. 2021 , 42, 2990-3004	2
267	Effects of concentrated ambient ultrafine particulate matter on hallmarks of Alzheimer's disease in the 3xTgAD mouse model. 2021 , 84, 172-183	2
266	Calcium Dyshomeostasis in Alzheimer's Disease Pathogenesis. 2021 , 22,	13
265	A Systematic Review of Glucose Transport Alterations in Alzheimer's Disease. 2021 , 15, 626636	8
264	Insulin Resistance as a Common Link Between Current Alzheimer's Disease Hypotheses. 2021 , 82, 71-105	7
263	Alzheimer and Purinergic Signaling: Just a Matter of Inflammation?. 2021 , 10,	4
262	Tau aggregates are RNA-protein assemblies that mislocalize multiple nuclear speckle components. 2021 , 109, 1675-1691.e9	27
261	Biomarkers and Tools for Predicting Alzheimer's Disease at the Preclinical Stage. 2021 ,	4
260	PET Neuroimaging of Alzheimer's Disease: Radiotracers and Their Utility in Clinical Research. 2021 , 13, 624330	5
259	Positive Effect of Cognitive Reserve on Episodic Memory, Executive and Attentional Functions Taking Into Account Amyloid-Beta, Tau, and Apolipoprotein E Status. 2021 , 13, 666181	2

258	Molecular imaging of beta-amyloid deposition in late-life depression. 2021 , 101, 85-93	8
257	Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. 2021 , 20, 484-496	86
256	Dual-Task Training Effect on Cognitive and Body Function, β amyloid Levels in Alzheimer's Dementia Patients: A Randomized Controlled Trial. 2021 , 33, 136-141	1
255	Amyloid- β a potential link between epilepsy and cognitive decline. 2021 , 17, 469-485	7
254	The BIN1 rs744373 Alzheimer's disease risk SNP is associated with faster A β associated tau accumulation and cognitive decline. 2021 ,	4
253	CSF1R inhibition rescues tau pathology and neurodegeneration in an A/T/N model with combined AD pathologies, while preserving plaque associated microglia. 2021 , 9, 108	7
252	Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer's Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression. 2021 , 22,	8
251	Pathological correlates of impaired self-awareness of memory function in Alzheimer's disease. 2021 , 13, 118	1
250	Higher CSF sTNFR1-related proteins associate with better prognosis in very early Alzheimer's disease. 2021 , 12, 4001	5
249	Microglia show differential transcriptomic response to A β peptide aggregates ex vivo and in vivo. 2021 , 4,	2
248	The changing definition of Alzheimer's disease. 2021 , 20, 414-415	3
247	Astrocyte-secreted glypican-4 drives APOE4-dependent tau pathology.	
246	Basal Forebrain Cholinergic Neurons: Linking Down Syndrome and Alzheimer's Disease. 2021 , 13, 703876	1
245	Brain Shape Changes Associated With Cerebral Atrophy in Healthy Aging and Alzheimer's Disease.. 2021 , 7,	5
244	Benefits in Alzheimer's Disease of Sensory and Multisensory Stimulation. 2021 , 82, 463-484	5
243	Amyloid- β and tau pathologies relate to distinctive brain dysconnectomics in preclinical autosomal-dominant Alzheimer's disease.	0
242	Amyloid- β A double agent in Alzheimer's disease?. 2021 , 139, 111575	9
241	Therapeutic Ultrasound as a Treatment Modality for Physiological and Pathological Ageing Including Alzheimer's Disease. 2021 , 13,	0

240	Tau pathology mediates the effects of amyloid on neocortical tau propagation and neurodegeneration among individuals without dementia.	
239	When Does Alzheimer's Disease Really Start? The Role of Biomarkers. 2021 , 19, 355-364	
238	Effects of monoclonal antibodies against amyloid- β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer's disease. 2021 , 68, 101339	24
237	Mediterranean and Western diet effects on Alzheimer's disease biomarkers, cerebral perfusion, and cognition in mid-life: A randomized trial. 2021 ,	3
236	Biomarkers for the Clinical Diagnosis of Alzheimer's Disease: Metabolomics Analysis of Brain Tissue and Blood. 2021 , 12, 700587	0
235	Evaluation of [18 F]-JNJ-64326067-AAA tau PET tracer in humans. 2021 , 41, 3302-3313	3
234	Association of Tau Pathology With Clinical Symptoms in the Subfields of Hippocampal Formation. 2021 , 13, 672077	1
233	Non-invasive imaging of tau-targeted probe uptake by whole brain multi-spectral optoacoustic tomography.	5
232	Topographical Overlapping of the Amyloid- β and Tau Pathologies in the Default Mode Network Predicts Alzheimer's Disease with Higher Specificity. 2021 , 83, 407-421	2
231	Longitudinal predictive modeling of tau progression along the structural connectome. 2021 , 237, 118126	1
230	Apolipoprotein E and Alzheimer's Disease: Findings, Hypotheses, and Potential Mechanisms. 2021 ,	7
229	Nonhuman primates at the intersection of aging biology, chronic disease, and health: An introduction to the American Journal of Primatology Special Issue on aging, cognitive decline, and neuropathology in nonhuman primates. 2021 , 83, e23309	2
228	Deficits in short-term memory binding are detectable in individuals with brain amyloid deposition in the absence of overt neurodegeneration in the Alzheimer's disease continuum. 2021 , 152, 105749	2
227	Amyloid-Targeting Drugs for the Treatment of Alzheimer Disease. 2021 , 39, 134-140	0
226	Associations Between Cognitive Complaints, Memory Performance, Mood, and Amyloid- β Accumulation in Healthy Amyloid Negative Late-Midlife Individuals. 2021 , 83, 127-141	0
225	Tau-PET and in vivo Braak-staging as prognostic markers of future cognitive decline in cognitively normal to demented individuals. 2021 , 13, 137	6
224	Genetic and environmental factors in Alzheimer's and Parkinson's diseases and promising therapeutic intervention via fecal microbiota transplantation. 2021 , 7, 70	5
223	Dynamic nanoassemblies for imaging and therapy of neurological disorders. 2021 , 175, 113832	0

222	Cortical hypometabolism reflects local atrophy and tau pathology in symptomatic Alzheimer's disease. 2021,		5
221	The Amyloid- β Pathway in Alzheimer's Disease. 2021,		63
220	Biomarkers for evaluating the effects of exercise interventions in patients with MCI or dementia: A systematic review and meta-analysis. 2021, 151, 111424		4
219	Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging. <i>JAMA Neurology</i> , 2021, 78, 961-971	17.2	29
218	US Food and Drug Administration Approval of Aducanumab-Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials?. <i>JAMA Neurology</i> , 2021, 78, 1307-1308	17.2	8
217	Association of CD2AP neuronal deposits with Braak neurofibrillary stage in Alzheimer's disease. 2021, e13016		1
216	Sirtuins as Potential Therapeutic Targets for Mitigating Neuroinflammation Associated With Alzheimer's Disease. 2021, 15, 746631		1
215	ApoE4 attenuates autophagy via FoxO3a repression in the brain. 2021, 11, 17604		3
214	Diagnosis and Treatment of Alzheimer's Disease:: An Update. 2021, 7, 74-85		1
213	Association of cortical microstructure with amyloid- β and tau: impact on cognitive decline, neurodegeneration, and clinical progression in older adults. 2021,		1
212	Selecting software pipelines for change in flortaucipir SUVR: Balancing repeatability and group separation. 2021, 238, 118259		4
211	Synaptic tau: A pathological or physiological phenomenon?. 2021, 9, 149		5
210	SIRT1 Regulates Tau Expression and Tau Synaptic Pathology. 2021, 84, 895-904		0
209	Current directions in tau research: Highlights from Tau 2020. 2021,		6
208	Tau deposition and structural connectivity demonstrate differential association patterns with neurocognitive tests. 2021, 1		
207	Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages. 2021,		6
206	Editorial: Tau Pathology in Neurological Disorders. 2021, 12, 754669		1
205	Content-specific vulnerability of recent episodic memories in Alzheimer's disease. 2021, 160, 107976		0

204	Identifying individuals with Alzheimer's disease-like brains based on structural imaging in the Human Connectome Project Aging cohort. 2021 , 42, 5535-5546	3
203	Is comprehensiveness critical? Comparing short and long format cognitive assessments in preclinical Alzheimer disease. 2021 , 13, 153	
202	Interplay of gut microbiota and oxidative stress: Perspective on neurodegeneration and neuroprotection.. 2022 , 38, 223-244	4
201	Abnormal tau in amyloid PET negative individuals. 2021 , 109, 125-134	0
200	Brain aging mechanisms with mechanical manifestations. 2021 , 200, 111575	8
199	Icariin ameliorate Alzheimer's disease by influencing SIRT1 and inhibiting A β cascade pathogenesis. 2021 , 117, 102014	1
198	Relationships between Amyloid and tau in an elderly population: An accelerated failure time model. 2021 , 242, 118440	1
197	Influence of common reference regions on regional tau patterns in cross-sectional and longitudinal [F]-AV-1451 PET data. 2021 , 243, 118553	4
196	Memory Binding. 2022 , 455-461	
195	The cortical origin and initial spread of medial temporal tauopathy in Alzheimer's disease assessed with positron emission tomography. 2021 , 13,	32
194	Current advances in digital cognitive assessment for preclinical Alzheimer's disease. 2021 , 13, e12217	6
193	The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects. 2020 , 143, 3805-3815	18
192	APOE interacts with tau PET to influence memory independently of amyloid PET.	2
191	Single-soma transcriptomics of tangle-bearing neurons in Alzheimer's disease reveals the signatures of tau-associated synaptic dysfunction.	12
190	Time course of phosphorylated tau181 in blood across the Alzheimer's disease spectrum.	2
189	Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer's Disease Neuroimaging Initiative.	1
188	Locus coeruleus integrity is related to tau burden and memory loss in autosomal-dominant Alzheimer's disease.	4
187	Multi-cellular communities are perturbed in the aging human brain and with Alzheimer's disease.	4

186	Detection of cerebral tauopathy in P301L mice using high-resolution large-field multifocal illumination fluorescence microscopy. 2020 , 11, 4989-5002	7
185	What Is T+? A Gordian Knot of Tracers, Thresholds, and Topographies. 2021 , 62, 614-619	5
184	Relationship Between Tau and Cognition in the Evolution of Alzheimer's Disease: New Insights from Tau PET. 2021 , 62, 612-613	4
183	An Overview of Several Inhibitors for Alzheimer's Disease: Characterization and Failure. 2021 , 22,	2
182	Alzheimer's disease clinical trial update 2019-2021. 2021 , 1	6
181	Cognitive reserve proxies, Alzheimer pathologies, and cognition. 2021 , 110, 88-95	2
180	Unmasking selective path integration deficits in Alzheimer's disease risk carriers.	0
179	Detection of cerebral tauopathy in P301L mice using high-resolution large-field multifocal illumination fluorescence microscopy.	1
178	Relationship between comprehensive geriatric assessment and amyloid PET in older persons with MCI.	
177	Predicting future regional tau accumulation in asymptomatic and early Alzheimer's disease.	1
176	Arginine and Arginine-Rich Peptides as Modulators of Protein Aggregation and Cytotoxicity Associated With Alzheimer's Disease. 2021 , 14, 759729	3
175	In vivo rate-determining steps of tau seed accumulation in Alzheimer's disease. 2021 , 7, eabh1448	10
174	Metacognition, cortical thickness, and tauopathy in aging.	
173	Relationship between comprehensive geriatric assessment and amyloid PET in older persons with MCI.	
172	Antisense oligonucleotide drugs for neurological and neuromuscular disease. 2020 , 221-245	
171	Clinical Research Progress of Alzheimer's Disease. 2020 , 10, 2254-2259	
170	Impact of the New Conceptual Framework of Alzheimer's Disease in Imaging Studies. 2021 , 427-451	
169	An insight into Alzheimer's disease and its on-setting novel genes. 2021 , 57,	2

168	Effects of Cigarette Smoking on Resting-State Functional Connectivity of the Nucleus Basalis of Meynert in Mild Cognitive Impairment. 2021 , 13, 755630	0
167	Heterogeneity of Tau Deposition and Microvascular Involvement in MCI and AD. 2021 ,	1
166	MR Brain Screening using Optimization Techniques - A survey. 2021 ,	
165	Tau Biomarkers in Dementia: Positron Emission Tomography Radiopharmaceuticals in Tauopathy Assessment and Future Perspective. 2021 , 22,	0
164	Baseline [F]GTP1 tau PET imaging is associated with subsequent cognitive decline in Alzheimer's disease. 2021 , 13, 196	2
163	Role of a EphA-4 receptor tyrosine kinase in the pathogenesis of Alzheimer's Disease.. 2022 ,	1
162	Can Exercise Training Teach Us How to Treat Alzheimer's disease?. 2022 , 75, 101559	0
161	Speech pause distribution as an early marker for Alzheimer's disease. 2022 , 136, 107-117	2
160	Heterogeneity in Alzheimer's Disease Diagnosis and Progression Rates: Implications for Therapeutic Trials.. 2022 , 1	2
159	Model-based stratification of progression along the Alzheimer disease continuum highlights the centrality of biomarker synergies.. 2022 , 14, 16	0
158	Amyloid-beta peptide and tau protein crosstalk in Alzheimer's disease.. 2022 , 17, 1666-1674	9
157	Plasma protein biomarker model for screening Alzheimer disease using multiple reaction monitoring-mass spectrometry.. 2022 , 12, 1282	0
156	N6-methyladenine-modified DNA was decreased in Alzheimer's disease patients.. 2022 , 10, 448-457	1
155	Positron Emission Tomography in Animal Models of Tauopathies.. 2021 , 13, 761913	3
154	Genetically identical twins show comparable tau PET load and spatial distribution.. 2022 ,	1
153	Monthly At-Home Computerized Cognitive Testing to Detect Diminished Practice Effects in Preclinical Alzheimer's Disease.. 2021 , 13, 800126	2
152	Recent Developments in Positron Emission Tomography Tracers for Proteinopathies Imaging in Dementia.. 2021 , 13, 751897	2
151	Characterising activity and diet compositions for dementia prevention: protocol for the ACTIVate prospective longitudinal cohort study.. 2022 , 12, e047888	0

150	Role of proline-rich tyrosine kinase 2 (Pyk2) in the pathogenesis of Alzheimer's Disease.. 2021 ,	0
149	Mechanistic and therapeutic role of Drp1 in the pathogenesis of Alzheimer's Disease.. 2022 ,	2
148	Locus coeruleus integrity is related to tau burden and memory loss in autosomal-dominant Alzheimer's disease.. 2021 , 112, 39-54	4
147	Cholinergic receptor binding in unimpaired older adults, mild cognitive impairment, and Alzheimer's disease dementia.. 2022 , 14, 25	2
146	Distinctive Temporal Trajectories of Alzheimer's Disease Biomarkers According to Sex and Genotype: Importance of Striatal Amyloid.. 2022 , 14, 829202	1
145	Non-invasive imaging of tau-targeted probe uptake by whole brain multi-spectral optoacoustic tomography.. 2022 , 1	2
144	Visit-to-Visit Blood Pressure Variability and Longitudinal Tau Accumulation in Older Adults.. 2021 , HYPERTENSION 12	1
143	A unifying framework for amyloid-mediated membrane damage: The lipid-chaperone hypothesis.. 2022 , 1870, 140767	2
142	NeuroXNet: Creating A Novel Deep Learning Architecture that Diagnoses Neurological Disorders, Finds New Blood Biomarkers, and Assesses Surgical, Drugs, and Radiation Treatment Plans Using Medical Imaging and Genomic Data.	
141	Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.. <i>JAMA Neurology</i> , 2021 ,	17.2 10
140	Tau Imaging with 18F-MK6240 across the Alzheimer's Disease spectrum.	1
139	Tracer-specific reference tissues selection improves detection of F-FDG, F-florbetapir, and F-flortaucipir PET SUVR changes in Alzheimer's disease.. 2022 ,	2
138	Impact of 40 Hz Transcranial Alternating Current Stimulation on Cerebral Tau Burden in Patients with Alzheimer's Disease: A Case Series.. 2021 ,	2
137	Epigenetic axis of SNHG19/miR-137/TNFAIP1 modulates amyloid beta peptide 25-35-induced SH-SY5Y cytotoxicity.. 2022 ,	0
136	Clear-headed into old age: Resilience and resistance against brain aging - A PET imaging perspective.. 2022 ,	0
135	Novel approaches to measuring neurocognitive functions in Alzheimer's disease clinical trials.. 2022 , 35,	1
134	CSF biomarkers and plasma p-tau181 as predictors of longitudinal tau accumulation: Implications for clinical trial design.. 2022 ,	3
133	Associations of Stages of Objective Memory Impairment (SOMI) with Amyloid PET and Structural MRI: The A4 Study.. 2022 ,	3

132	Racial differences in longitudinal Alzheimer’s disease biomarkers among cognitively normal adults.. 2022,	1
131	MEG Oscillatory Slowing in Cognitive Impairment is Associated with the Presence of Subjective Cognitive Decline.. 2022, 15500594221072708	1
130	The Trajectory of Cerebrospinal Fluid Growth-Associated Protein 43 in the Alzheimer’s Disease Continuum: A Longitudinal Study.. 2021,	1
129	A Pathway-Specific Polygenic Risk Score is Associated with Tau Pathology and Cognitive Decline.. 2021,	0
128	The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics.. 2022,	24
127	Redox signaling at the crossroads of human health and disease.. 2022, 3, e127	7
126	Characterizing Amyloid Positive Individuals With Normal Tau PET Levels After 5 Years: An ADNI Study.. 2022,	1
125	2022 Alzheimer’s disease facts and figures.. 2022,	95
124	Tau Toxicity in Neurodegeneration.. 2022, 1	1
123	Quantitative and histologically validated measures of the entorhinal subfields in ex vivo MRI.	1
122	Safety and Efficacy of Monoclonal Antibodies for Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Published and Unpublished Clinical Trials.. 2022,	3
121	Knockout of TSPO delays and reduces amyloid, Tau, astrocytosis and behavioral dysfunctions in Alzheimer’s disease.	
120	Inhibition of CK2 mitigates Alzheimer’s tau pathology by preventing NR2B synaptic mislocalization.. 2022, 10, 30	1
119	Examining the association between blood-based biomarkers and human post mortem neuropathology in the University of Kentucky Alzheimer’s Disease Research Center autopsy cohort.. 2022,	0
118	Association of Emerging β Amyloid and Tau Pathology With Early Cognitive Changes in Clinically Normal Older Adults.. 2022,	1
117	Seed amplification and RT-QuIC assays to investigate protein seed structures and strains.. 2022, 1	0
116	β Amyloid discordance of cerebrospinal fluid and positron emission tomography imaging shows distinct spatial tau patterns.. 2022, 4, fcac084	0
115	[Diagnosing Alzheimer Dementia in People with Down Syndrome in Accordance with ICD, DSM V and A/T/N System].. 2022,	0

114	A robust and interpretable machine learning approach using multimodal biological data to predict future pathological tau accumulation.. 2022 , 13, 1887	2
113	Tauopathies: new perspectives and challenges.. 2022 , 17, 28	8
112	Amyloid- β and tau pathologies relate to distinctive brain dysconnectomics in preclinical autosomal-dominant Alzheimer's disease.. 2022 , 119, e2113641119	2
111	Distinct factors drive the spatiotemporal progression of tau pathology in older adults.. 2021 ,	0
110	Alzheimer's disease biomarkers in Black and non-Hispanic White cohorts: A contextualized review of the evidence. 2021 ,	4
109	Tau polygenic risk scoring: a cost-effective aid for prognostic counseling in Alzheimer's disease.. 2022 , 143, 571	0
108	Current trends in blood biomarker detection and imaging for Alzheimer's disease.. 2022 , 210, 114278	1
107	Data_Sheet_1.PDF. 2019 ,	
106	Table_1.DOCX. 2019 ,	
105	Table_1.pdf. 2020 ,	
104	Alzheimer's Disease: A Washing Machine on the Fritz. 2022 , 12, 131-163	0
103	Blood Phosphorylated Tau 181 as a Biomarker for Amyloid Burden on Brain PET in Cognitively Healthy Adults.. 2022 ,	0
102	Loss of perivascular aquaporin-4 localization impairs glymphatic exchange and promotes amyloid β plaque formation in mice.. 2022 , 14, 59	4
101	Parvalbumin neuroplasticity compensates for somatostatin impairment, maintaining cognitive function in Alzheimer's disease.. 2022 , 11, 26	0
100	Commentary: Aducanumab-Related ARIA: Paean or Lament?. 2022 ,	1
99	Amyloid, cerebrovascular disease, and neurodegeneration biomarkers are associated with cognitive trajectories in a racially and ethnically diverse, community-based sample. 2022 ,	0
98	Biomarker Candidates for Alzheimer's Disease Unraveled through In Silico Differential Gene Expression Analysis. 2022 , 12, 1165	
97	Sex Differences for Clinical Correlates of Alzheimer's Pathology in People with Lewy Body Pathology.. 2022 ,	0

- 96 What contribution can genetics make to predict the risk of Alzheimer's disease?. **2022**, 1
- 95 Tau Aggregation Inhibiting Peptides as Potential Therapeutics for Alzheimer Disease. 1
- 94 Spatial normalization and quantification approaches of PET imaging for neurological disorders. 0
- 93 The future of stem cell therapies of Alzheimer's disease. **2022**, 101655 1
- 92 The Gut Microbiota-Brain Axis: A New Frontier on Neuropsychiatric Disorders. **2022**, 13, 0
- 91 Tau Beats Amyloid in Predicting Brain Atrophy in Alzheimer Disease: Implications for Prognosis and Clinical Trials. **2022**, 63, 830-832
- 90 Functional Connectivity Dynamics Altered of the Resting Brain in Subjective Cognitive Decline. 14,
- 89 Identification of sulfonamide-based butyrylcholinesterase inhibitors using machine learning.
- 88 Molecular PET Imaging in Alzheimer's Disease. 0
- 87 A multi-omics approach identifies a blood-based miRNA signature of cognitive decline in two large observational trials.
- 86 Advances in the Functions of Thioredoxin System in Central Nervous System Diseases. 0
- 85 Metacognition, cortical thickness, and tauopathy in aging. **2022**,
- 84 Amyloid, tau and metabolic PET correlates of cognition in early and late-onset Alzheimer's disease. 0
- 83 Sex differences in plasma p-tau181 associations with Alzheimer's disease biomarkers, cognitive decline, and clinical progression. 0
- 82 Phenazopyridine promotes RPS23RG1/Rps23rg1 transcription and ameliorates Alzheimer-associated phenotypes in mice.
- 81 Blood-based A β 2 increases in the earliest pre-pathological stage before decreasing with progressive amyloid pathology in preclinical models and human subjects: opening new avenues for prevention. 1
- 80 AMYLOID- β AND TAU DEPOSITION INFLUENCES COGNITIVE AND FUNCTIONAL DECLINE IN DOWN SYNDROME. **2022**,
- 79 The unique effect of TDP-43 on hippocampal subfield morphometry and cognition. **2022**, 103125

78	Causal links among amyloid, tau, and neurodegeneration.	0
77	Molecular signatures underlying neurofibrillary tangle susceptibility in Alzheimer's disease. 2022,	1
76	Preclinical Alzheimer's disease biomarkers accurately predict cognitive and neuropathological outcomes.	0
75	Evaluation of tau deposition using 18F-PI-2620 PET in MCI and early AD subjects's MissionAD tau sub-study. 2022, 14,	0
74	Association of Carotid Intima Media Thickening with Future Brain Region Specific Amyloid- β Burden. 2022, 1-10	
73	Portable Vertical Graphene@Au-Based Electrochemical Aptasensing Platform for Point-of-Care Testing of Tau Protein in the Blood. 2022, 12, 564	2
72	Sirtuins promote brain homeostasis, preventing Alzheimer's disease through targeting neuroinflammation. 13,	0
71	Induction of A Disintegrin and Metalloproteinase with Thrombospondin motifs 1 by a rare variant or cognitive activities reduces hippocampal amyloid- β and consequent Alzheimer's disease risk. 14,	
70	The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer's disease.	2
69	Astrocyte-secreted glypican-4 drives APOE4-dependent tau hyperphosphorylation. 2022, 119,	0
68	Accelerated longitudinal changes and ordering of Alzheimer disease biomarkers across the adult lifespan.	0
67	Spatial Extent of Amyloid- β Levels and Associations With Tau-PET and Cognition.	0
66	USP10 deubiquitinates Tau, mediating its aggregation. 2022, 13,	0
65	The Impairment of Blood-Brain Barrier in Alzheimer's Disease: Challenges and Opportunities with Stem Cells. 2022, 23, 10136	1
64	Default-mode network connectivity changes during the progression towards Alzheimer's dementia: A longitudinal functional MRI study.	0
63	Effect and Mechanism of Exogenous Melatonin on Cognitive Deficits in Animal Models of Alzheimer's Disease: A Systematic review and Meta-analysis. 2022,	0
62	Synthesizing Images of Tau Pathology from Cross-modal Neuroimaging using Deep Learning.	0
61	A head-to-head comparison between plasma pTau181 and tau-PET along the Alzheimer's disease continuum. jnumed.122.264279	0

60	Semiquantitative Approach to Amyloid Positron Emission Tomography Interpretation in Clinical Practice.	0
59	Piperazine Derivative Stabilizes Actin Filaments in Primary Fibroblasts and Binds G-Actin In Silico. 2022 , 44, 5191-5208	0
58	An Emerging Role for Stress Granules in Neurodegenerative Disease and Hearing Loss. 2022 , 108634	1
57	Plasma A β ₂ /A β ₀ and p-tau 181 Predict Long-Term Clinical Progression in a Cohort with Amnesic Mild Cognitive Impairment.	0
56	Unravelling the relationship between amyloid accumulation and brain network function in normal aging and very mild cognitive decline: a longitudinal analysis.	0
55	The central role of tau in Alzheimer's disease: From neurofibrillary tangle maturation to the induction of cell death. 2022 , 190, 204-217	2
54	SPARE-Tau: A flortaucipir machine-learning derived early predictor of cognitive decline. 2022 , 17, e0276392	0
53	Combination of Alpinia Oxyphylla Fructus and Schisandra Chinensis Fructus ameliorates aluminum-induced Alzheimer's disease via reducing BACE1 expression. 2022 , 126, 102180	0
52	Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline.	2
51	Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer's disease. 2022 , 13,	2
50	Focus on Alzheimer's disease: the role of fibroblast growth factor 21 and autophagy. 2022 ,	0
49	Longitudinal CSF Alzheimer's disease biomarker changes from middle age to late adulthood. 2022 , 14,	0
48	Kinetic evaluation and assessment of longitudinal changes in reference region and extracerebral [18F]MK-6240 PET uptake. 0271678X2211421	1
47	Tau depletion in human neurons mitigates A beta-driven toxicity.	0
46	Microbiome and Metabolome Insights into the Role of the Gastrointestinal Brain Axis in Parkinson's and Alzheimer's Disease: Unveiling Potential Therapeutic Targets. 2022 , 12, 1222	0
45	Therapeutic Mechanism of Kai Xin San on Alzheimer's Disease Based on Network Pharmacology and Experimental Validation.	0
44	Iron and Alzheimer's Disease. 2023 , 139-170	0
43	Capillary dysfunction correlates with cortical amyloid load in early Alzheimer's Disease. 2022 ,	0

- 42 Neural atrophy produced by AAV tau injections into hippocampus and anterior cortex of middle-aged mice. **2022**, ○
- 41 Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography. 1
- 40 Quantitative proteomics of cerebrospinal fluid from African Americans and Caucasians reveals shared and divergent changes in Alzheimer's disease. ○
- 39 Genetic risk for attention-deficit/hyperactivity disorder predicts cognitive decline and development of Alzheimer's disease pathophysiology in cognitively unimpaired older adults. ○
- 38 Models of Neurodegenerative Diseases. **2023**, 179-209 ○
- 37 Medial temporal tau predicts memory decline in cognitively unimpaired elderly. ○
- 36 Dyslipidemia induced large-scale network connectivity abnormality facilitates cognitive decline in the Alzheimer's disease. **2022**, 20, ○
- 35 APOE effects on regional tau in preclinical Alzheimer's disease. **2023**, 18, ○
- 34 Associations between cortical β amyloid burden, fornix microstructure and cognitive processing of faces, places, bodies and other visual objects in early Alzheimer's disease. ○
- 33 Evolutionary and genomic perspectives of brain aging and neurodegenerative diseases. **2023**, ○
- 32 Investigation of Cannabis sativa Phytochemicals as Anti-Alzheimer's Agents: An In Silico Study. **2023**, 12, 510 ○
- 31 How does apolipoprotein E genotype influence the relationship between physical activity and Alzheimer's disease risk? A novel integrative model. **2023**, 15, ○
- 30 Discriminative accuracy of the A/T/N scheme to identify cognitive impairment due to Alzheimer's disease. **2023**, 15, ○
- 29 Tau, RNA, and RNA-Binding Proteins: Complex Interactions in Health and Neurodegenerative Diseases. 107385842311545 ○
- 28 Genetically identical twin-pair difference models support the amyloid cascade hypothesis. ○
- 27 Ethnobotanical significance of medicinal plants: Beta-amyloid and tau aggregation inhibitors against Alzheimer's disease. ○
- 26 Reduction in GABAB on glia induce Alzheimer's disease related changes. **2023**, 110, 260-275 ○
- 25 Role of microbial dysbiosis in the pathogenesis of Alzheimer's disease. **2023**, 229, 109478 ○

24	Imaging Amyloid and Tau in the Retina: Current Research and Future Directions. 2023 , Publish Ahead of Print,	0
23	Rates of regional tau accumulation in ageing and across the Alzheimer's disease continuum: an AIBL 18F-MK6240 PET study. 2023 , 88, 104450	0
22	Astrocyte reactivity influences the association of amyloid- β and tau biomarkers in preclinical Alzheimer's disease.	0
21	Effect of Pathway-specific Polygenic Risk Scores for Alzheimer's Disease (AD) on Rate of Change in Cognitive Function and AD-related Biomarkers among Asymptomatic Individuals.	0
20	Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers. 2023 , 80, 360	1
19	Development, initial validation, and application of a visual read method for [¹⁸ F]MK-6240 tau PET. 2023 , 9,	1
18	Effect of sulfonamide derivatives of phenylglycine on scopolamine-induced amnesia in rats. 2023 , 9, 13-31	0
17	Amyloid- β /Tau burden and neuroinflammation dual-targeted nanomedicines synergistically restore memory and recognition of Alzheimer's disease mice. 2023 , 49, 101788	0
16	Contribution of Alzheimer's disease pathology to biological and clinical progression: A longitudinal study across two cohorts.	0
15	Early tau detection in flortaucipir images: validation in autopsy-confirmed data and implications for disease progression. 2023 , 15,	0
14	CREB3L2-ATF4 heterodimerization defines a transcriptional hub of Alzheimer's disease gene expression linked to neuropathology. 2023 , 9,	0
13	2023 Alzheimer's disease facts and figures. 2023 , 19, 1598-1695	1
12	Association of subclinical depressive symptoms and sleep with cognition in the community-dwelling older adults. 2023 ,	0
11	Purposed potential Alzheimer's Disease treatment based on the results from current primary research models. 36, 969-977	0
10	Influence of Host Age on Intracranial AAV9 TauP301L Induced Tauopathy. 2023 , 1-14	0
9	Astrocytic APOE4 removal confers cerebrovascular protection despite increased cerebral amyloid angiopathy. 2023 , 18,	0
8	Disentangling the distal association between β Amyloid and tau pathology at varying stages of tau deposition.	0
7	Association between gray matter atrophy, cerebral hypoperfusion, and cognitive impairment in Alzheimer's disease. 15,	0

- 6 Insights from Drosophila on A β and tau-induced mitochondrial dysfunction: mechanisms and tools. 17,
- 5 Should artificial intelligence be used in conjunction with Neuroimaging in the diagnosis of Alzheimer's disease?. 15,
- 4 Accelerated long-term forgetting: A sensitive paradigm for detecting subtle cognitive impairment and evaluating BACE1 inhibitor efficacy in preclinical Alzheimer's disease. 2,
- 3 Biomarkers of aging.
- 2 Proteostasis failure exacerbates neuronal circuit dysfunction and sleep impairments in Alzheimer's disease. **2023**, 18,
- 1 The Multifaceted Role of WNT Signaling in Alzheimer's Disease Onset and Age-Related Progression. **2023**, 12, 1204